Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myeloid, Acute 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Testicular Neoplasms 1Teratoma, Testicular 1Teratoma 1Sezary Syndrome 1Seminoma 1Pulmonary Aspergillosis 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Neutropenia 1Neuroblastoma 1Neoplasms 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Mycoses 1Multiple Myeloma 1Mucormycosis 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1

Interventions

Cyclophosphamide 72fludarabine 65Tacrolimus 43fludarabine phosphate 40Whole-Body Irradiation 37Mycophenolic Acid 35Busulfan 32Melphalan 28Antilymphocyte Serum 23thymoglobulin 22Thiotepa 20Methotrexate 20Standard of Care 19Stem Cell Transplantation 17Practice Guidelines as Topic 17Granulocyte Colony-Stimulating Factor 17Rituximab 15Surveys and Questionnaires 12Sirolimus 12Filgrastim 12Interviews as Topic 11Cyclosporine 11Blood Specimen Collection 11Peripheral Blood Stem Cell Transplantation 10Exercise 10venetoclax 9Mesna 9Cytarabine 9Bortezomib 9Hematopoietic Stem Cell Transplantation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hematologic Neoplasms × liposomal amphotericin B × Clear all
NCT07185503 2025-09-22

Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety

Institute of Hematology & Blood Diseases Hospital, China

Recruiting
60 enrolled
Other hematologic neoplasm

Mucormycosis, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡